<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570735</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02750-57</org_study_id>
    <nct_id>NCT04570735</nct_id>
  </id_info>
  <brief_title>MRI Biomarkers in Diabetic Kidney Disease</brief_title>
  <acronym>MR3T - DKD</acronym>
  <official_title>MRI Biomarkers in Diabetic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic kidney disease is one of the most severe and frequent complications of diabetes. Few&#xD;
      preclinical markers are available apart from plasma creatinine and microalbuminuria. These&#xD;
      markers are imperfect (some patients with advanced renal disease do not have an increase in&#xD;
      markers) and late. Therefor there is an uncovered need to identify complementary biomarkers.&#xD;
      Magnetic Resonance Spectroscopy (MRS) is a Magnetic Resonance Imaging (MRI) technique that&#xD;
      allows the physiology and biochemistry of human body tissues to be studied in a non-invasive&#xD;
      and non-irradiating manner.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">October 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 7, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between morphometric and functional and metabolic biomarker data obtained by magnetic resonance spectroscopy (MRS) in 3 different patient groups</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between MRS biomarkers and annual glomerural filtration rate slope calculated within 3 previous years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between metabolic MRS biomarkers and urine and plasma metabolites quantification.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>patients with type 2 diabetes and diabetic kidney disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with type 2 diabetes and no diabetic kidney disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with obesity, no diabetes and no kidney disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI</description>
    <arm_group_label>patients with obesity, no diabetes and no kidney disease</arm_group_label>
    <arm_group_label>patients with type 2 diabetes and diabetic kidney disease</arm_group_label>
    <arm_group_label>patients with type 2 diabetes and no diabetic kidney disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes with or without diabetic kidney disease and patients with&#xD;
        obesity and no diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Common to all 3 category&#xD;
&#xD;
          -  Male or female,&#xD;
&#xD;
          -  Age≥ 35 years,&#xD;
&#xD;
          -  Subject free, with legal protection guardianship or curatorship;&#xD;
&#xD;
          -  Enrollment in the French Social Security system;&#xD;
&#xD;
          -  Informed consent signed by the patient&#xD;
&#xD;
        Obese patients&#xD;
&#xD;
          -  BMI &gt;30 kgm² ;&#xD;
&#xD;
          -  With no known diabetes;&#xD;
&#xD;
          -  estimated glomerular filtration rate (eGFR) &gt; 60 ml/min/1.73m² and urine&#xD;
             albumin-creatinin ratio (ACR) &lt; 3 mg/g&#xD;
&#xD;
        Type 2 diabetic patients without kidney disease&#xD;
&#xD;
        - eGFR &gt; 60 ml/min/1.73m² AND ACR &lt; 3 mg/g,&#xD;
&#xD;
        Type 2 diabetic patients with diabetic kidney disease defined as eGFR 30 to 60&#xD;
        ml/min/1.73m² OR ACR &gt; 30 mg/mmol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Age &lt; 35 years History of kidney transplant Any contraindication to an MRI examination&#xD;
        Legal protection, namely minors, persons deprived of their liberty by a judicial or&#xD;
        administrative decision, persons residing in a health or social establishment, adults under&#xD;
        legal protection and finally patients in emergency situations Pregnant or lactating women,&#xD;
        women of childbearing age who do not have effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Jean Saulnier, M.D. Ph.D.</last_name>
    <phone>+33 5 49 44 46 89</phone>
    <email>pierre-jean.saulnier@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Jean SAULNIER</last_name>
      <email>pierre-jean.saulnier@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>diabetic nephropathies</keyword>
  <keyword>biomarkers</keyword>
  <keyword>metabolites</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

